PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8233444

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT @ REEL 061803 AND FRAME 0878

CONVEYING PARTY DATA

Name	Execution Date
WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT	10/18/2023

RECEIVING PARTY DATA

Name:	PTC THERAPEUTICS, INC.	
Street Address:	100 CORPORATE COURT	
City:	SOUTH PLAINFIELD	
State/Country:	NEW JERSEY	
Postal Code:	07080	

PROPERTY NUMBERS Total: 81

Property Type	Number
Patent Number:	7202262
Patent Number:	8227494
Patent Number:	9205088
Patent Number:	7772259
Patent Number:	8796322
Patent Number:	8486982
Patent Number:	6992096
Patent Number:	8129540
Patent Number:	8716321
Patent Number:	9474743
Patent Number:	10285980
Patent Number:	10675272
Patent Number:	10034863
Patent Number:	7419991
Patent Number:	8367841
Patent Number:	7678922
Patent Number:	8748625
Patent Number:	9309206
Patent Number:	10028939

PATENT

REEL: 065303 FRAME: 0163

Property Type	Number
Patent Number:	7863456
Patent Number:	9447006
Patent Number:	11021424
Patent Number:	8106223
Patent Number:	8575369
Patent Number:	10071978
Patent Number:	11312697
Patent Number:	9162957
Patent Number:	9567279
Patent Number:	10029971
Patent Number:	10202325
Patent Number:	10745371
Patent Number:	11186559
Patent Number:	7291461
Patent Number:	7927791
Patent Number:	8975287
Patent Number:	9861617
Patent Number:	10071081
Patent Number:	7304080
Patent Number:	10300047
Patent Number:	10959988
Patent Number:	8394966
Patent Number:	7683082
Patent Number:	8017636
Patent Number:	8299105
Patent Number:	8163782
Patent Number:	9522137
Patent Number:	9737513
Patent Number:	9877952
Patent Number:	10172836
Patent Number:	10849885
Patent Number:	9226919
Patent Number:	10233161
Patent Number:	9873677
Patent Number:	10618877
Patent Number:	10517853
Patent Number:	8952071
Patent Number:	9090576

Property Type	Number
Patent Number:	9073873
Patent Number:	9370496
Patent Number:	10195161
Patent Number:	10189830
Patent Number:	7491312
Patent Number:	10039722
Patent Number:	9464016
Patent Number:	10703701
Patent Number:	10981855
Patent Number:	8716527
Patent Number:	11083737
Application Number:	16866822
Application Number:	17602576
Application Number:	17216502
Application Number:	14038675
Application Number:	17699061
Application Number:	17511432
Application Number:	15776343
Application Number:	17078092
Application Number:	17490725
Application Number:	17183342
Application Number:	17334601
Application Number:	17400028
Application Number:	17394039

CORRESPONDENCE DATA

Fax Number: (617)526-5000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 720-274-3163

Email: JANEY.DAVIDSON@WILMERHALE.COM
Correspondent Name: BENJAMIN S. FERNANDEZ, ESQUIRE

Address Line 1: WILMER CUTLER PICKERING HALE AND DORR LLP

Address Line 2: 60 STATE STREET

Address Line 4: BOSTON, MASSACHUSETTS 02109

ATTORNEY DOCKET NUMBER:	290806.184
NAME OF SUBMITTER:	BENJAMIN S. FERNANDEZ
SIGNATURE:	/s/ Benjamin S. Fernandez
DATE SIGNED:	10/20/2023

Total Attachments: 15 source=release pat wt ptc#page1.tif source=release pat wt ptc#page2.tif source=release pat wt ptc#page3.tif source=release pat wt ptc#page4.tif source=release pat wt ptc#page5.tif source=release pat wt ptc#page6.tif source=release pat wt ptc#page7.tif source=release pat wt ptc#page8.tif source=release pat wt ptc#page9.tif source=release pat wt ptc#page10.tif source=release pat wt ptc#page11.tif source=release pat wt ptc#page12.tif source=release pat wt ptc#page13.tif source=release pat wt ptc#page14.tif source=release pat wt ptc#page15.tif

TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT

This **TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT** (this "*Termination and Release*") is granted as of October <u>18</u>, 2023 by **WILMINGTON TRUST, NATIONAL ASSOCIATION** ("Adminstrative Agent"), in favor of **PTC THERAPEUTICS, INC.**, a Delaware corporation ("Grantor").

WHEREAS, the Grantor executed and delivered a Patent Security Agreement, dated as of October 27, 2022 (the "Agreement"), granting to the Adminstrative Agent a security interest in all of its right, title and interest, whether presently existing or hereafter acquired, in, to and under the Patent Collateral (as defined in the Agreement), notice of which was recorded with the United States Patent and Trademark Office ("USPTO") on October 28, 2022, at Reel 061803, Frame 0878.

WHEREAS, Grantor has requested that Administrative Agent hereby terminate, release and discharge fully its security interests in and liens on all right, title and interest of Grantor in, to and under all of the Patent Collateral as herein provided; and

WHEREAS, Grantor has requested that the Administrative Agent provide a document suitable for recording with the USPTO to evidence the release of the Administrative Agent's security interests in and liens on the Patent Collateral as herein provided.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby:

- 1. terminates the Agreement and releases, terminates and discharges fully all liens and security interests thereunder in Grantor's right, title and interest in, to and under the Patent Collateral, including, without limitation, those patents and patent applications identified in Schedule I hereto; and
- 2. authorizes and requests that this Termination and Release be recorded with the USPTO.

This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows]

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

WILMINGTON TRUST, NATIONAL ASSOCIATION

Name: Andrew Lennon

Title: Assistante Vice President

SCHEDULE I TO TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT

Item A. <u>Patents</u>.

Issued Patents

Country	Patent No.	Issue Date	Inventor(s)	<u>Title</u>
US	7202262	04/10/2007	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	BENZOIC ACID OR BENZOATE SUBSTITUTED 1,2,4- OXADIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF DISEASE
US	8227494	07/24/2012	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	PHARMACEUTICAL COMPOSITIONS OF 1,2,4- OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE
US	9205088	12/08/2015	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	COMPOSITIONS OF 1,2,4- OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE
US	7772259	08/10/2010	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead	1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE

US	8796322	08/05/2014	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	METHODS FOR USING 1,2,4- OXADIAZOLE BENZOIC ACID COMPOUNDS
US	8486982	07/16/2013	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	1,2,4-OXADIAZOLE BENZOIC ACIDS
US	6992096	01/31/2006	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE
US	8129540	03/06/2012	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS
US	8716321	05/06/2014	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE
US	9474743	10/25/2016	Samit Hirawat; Langdon Miller	COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR THE TREATMENT OF DISEASE
US	10285980	05/14/2019	Samit Hirawat; Langdon Miller	COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-

				OXADIAZOLE FOR THE TREATMENT OF DISEASE
US	10675272	06/09/2020	Samit Hirawat; Langdon Miller	COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR THE TREATMENT OF DISEASE
US	10034863	07/31/2018	Samit Hirawat; Langdon Miller	COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE
US	7419991	09/02/2008	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	3-[5-(2-FLUORO-PHENYL)- [1,2,4]OXADIAZOL-3-YL]- BENZOIC ACID, COMPOSITIONS, AND METHODS FOR THE USE THEREOF
US	8367841	02/05/2013	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon; James J. Takasugi	PROCESSES FOR THE PREPARATION OF 1,2,4- OXADIAZOLE BENZOIC ACIDS
US	7678922	03/16/2010	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon; James J. Takasugi	PROCESSES FOR THE PREPARATION OF 1,2,4- OXADIAZOLE BENZOIC ACIDS
US	8748625	06/10/2014	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5- (2-FLUOROPHENYL)- [1,2,4]OXADIAZOL-3-YL]- BENZOIC ACID
US	9309206	04/12/2016	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5- (2-FLUOROPHENYL)-[1,2,4] OXADIAZOL-3-YL]-BENZOIC ACID
US	10028939	07/24/2018	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5- (2-FLUOROPHENYL)- [1,2,4]OXADIAZOL-3-YL]- BENZOIC ACID FOR THE TREATMENT OF DISEASE

US	7863456	01/04/2011	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5- (2-FLUOROPHENYL)- [1,2,4]OXADIAZOL-3-YL]- BENZOIC ACID
US	9447006	09/20/2016	Guy M. Miller Sidney M. Hecht	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
US	11021424	06/01/2021	Guy M. Miller Sidney M. Hecht	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
US	8106223	01/31/2012	Kieron E. Wesson; Andrew W. Hinman; Orion D. Jankowski	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
US	8575369	11/05/2013	Kieron E. Wesson; Andrew W. Hinman; Orion D. Jankowski	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
US	10071978	09/11/2018	Kieron E. Wesson; Andrew W. Hinman; Orion D. Jankowski	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
US	11312697	04/26/2022	Kieron E. Wesson; Andrew W. Hinman; Orion D. Jankowski	PROCESS FOR THE PRODUCTION OF ALPHA- TOCOTRIENOL AND DERIVATIVES
US	9162957	10/20/2015	Paul Mollard	METHODS FOR OXIDATION OF ALPHA TOCOTRIENOL IN THE

				PRESENCE OF NON-ALPHA TOCOTRIENOLS
US	9567279	02/14/2017	Paul Mollard	METHODS FOR OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
US	10029971	07/24/2018	Paul Mollard	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
US	10202325	02/12/2019	Paul Mollard	METHODS FOR SELECTIVE OXIDATION OF ALPHA TOCOTRIENOL IN THE PRESENCE OF NON-ALPHA TOCOTRIENOLS
US	10745371	08/18/2020	Peter Giannousis; Paul Mollard; Noah M. Benjamin; Jeffrey D. Butler; Olivier Dapremont; James B. Falabella	METHODS FOR ENRICHING ALPHA-TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
US	11186559	11/30/2021	Peter Giannousis; Paul Mollard; Noah M. Benjamin; Jeffrey D. Butler; Olivier Dapremont; James B. Falabella	METHODS FOR ENRICHING ALPHA-TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
US	7291461	11/06/2007	Ellen Welch; Jin Zhuo	METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MRNA DECAY
US	7927791	04/19/2011	Ellen M. Welch; Neil Gregory Almstead; Robert F. Rando; Mathew C. Pellegrini	METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED MRNA DECAY

US	8975287	03/10/2015	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	METHODS FOR USING 1,2,4- OXADIAZOLE BENZOIC ACID COMPOUNDS
US	9861617	01/09/2018	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	COMPOSITIONS OF 1,2,4- OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE
US	10071081	09/11/2018	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	COMPOSITIONS OF 1,2,4- OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE
US	7304080	12/04/2007	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	SUBSTITUTED 1,2,4- OXADIAZOLES, COMPOSITIONS AND METHODS OF USE
US	10300047	05/28/2019	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE
US	10959988	03/30/2021	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE

US	8394966	03/12/2013	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5- (2-FLUOROPHENYL)- [1,2,4]OXADIAZOL-3-YL]- BENZOIC ACID
US	7683082	03/23/2010	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS
US	8017636	09/13/2011	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS
US	8299105	10/30/2012	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS
US	8163782	04/24/2012	Gary Mitchell Karp; Seongwoo Hwang; Guangming Chen; Neil Gregory Almstead; Young-choon Moon	1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS
US	9522137	12/20/2016	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR NONSENSE

				MUTATION SUPPRESSION
				THERAPY
US	9737513	08/22/2017	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY
US	9877952	01/30/2018	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY
US	10172836	01/08/2019	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY
US	10849885	12/01/2020	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY
US	9226919	01/05/2016	Samit Hirawat; Langdon Miller	Methods for dosing an orally active 1,2,4-oxadiazole
US	10233161	03/19/2019	Maria L. Weetall; Ellen Welch; Mandar V. Dali; James Takasugi	PHARMACEUTICAL COMPOSITIONS AND SALTS OF A 1,2,4-OXADIAZOLE BENZOIC ACID
US	9873677	01/23/2018	Maria L. Weetall; Ellen Welch; Mandar V. Dali; James Takasugi	PHARMACEUTICAL COMPOSITIONS AND SALTS OF A 1,2,4-OXADIAZOLE BENZOIC ACID
US	10618877	04/14/2020	Maria L. Weetall; Ellen Welch; Mandar V. Dali;	PHARMACEUTICAL COMPOSITIONS AND SALTS OF

			James Takasugi	A 1,2,4-OXADIAZOLE BENZOIC ACID
US	10517853	12/31/2019	Ellen Welch; Yuki Tomizawa; Priya Vazirani	METHODS FOR TREATING EPILEPSY
US	8952071	02/10/2015	Andrew W. Hinman; Kieron E. Wesson	(HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
US	9090576	07/28/2015	Andrew W. Hinman; Kieron E. Wesson; Orion D. Jankowski; William D. Shrader; Edgar P. Lee	2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US	9073873	07/07/2015	Andrew W. Hinman; Orion D. Jankowski Kieron E. Wesson	2- HETEROCYCLYLAMINOALKYL- (P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US	9370496	06/21/2016	Guy M. Miller	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
US	10195161	02/05/2019	Guy M. Miller	TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
US	10189830	01/29/2019	Andrew W. Hinman;	ALKYL-HETEROARYL SUBSTITUTED QUINONE

			Kieron E.	DERIVATIVES FOR
			Wesson;	TREATMENT OF OXIDATIVE
			Christopher R.	STRESS DISORDERS
			Cornell	STALISS DISONDERS
US	7491312	02/17/2009	Sylvain Gilat;	IDENTIFYING THERAPEUTIC
			Gary Binyamin;	COMPOUNDS BASED ON THEIR
			Guy Miller	PHYSICAL-CHEMICAL
				PROPERTIES
		0010=10010		
US	10039722	08/07/2018	Guy M. Miller	TREATMENT OF OXIDATIVE
				STRESS DISORDERS
				INCLUDING CONTRAST
				NEPHROPATHY, RADIATION
				DAMAGE AND DISRUPTIONS IN
***	0.464016	10/11/2016	D 136 11 1	THE FUNCTION OF RED CELLS
US	9464016	10/11/2016	Paul Mollard;	CATECHOL DERIVATIVES FOR
			Gloria Pfister	TREATMENT OF OXIDATIVE
770	10702701	07/07/2020		STRESS DISEASES
US	10703701	07/07/2020	Andrew W.	FLUOROALKYL,
			Hinman;	FLUOROALKOXY, PHENOXY,
			Steven J.	HETEROARYLOXY, ALKOXY,
			Richards	AND AMINE 1,4-
				BENZOQUINONE DERIVATIVES
				FOR TREATMENT OF
				OXIDATIVE STRESS
				DISORDERS
US	10981855	07/07/2020	Andrew W.	FLUOROALKYL,
			Hinman;	FLUOROALKOXY, PHENOXY,
			Steven J.	HETEROARYLOXY, ALKOXY,
			Richards	AND AMINE 1,4-
				BENZOQUINONE DERIVATIVES
				FOR TREATMENT OF
				OXIDATIVE STRESS
		0.7/0.5/5-5-5		DISORDERS
US	8716527	05/06/2014	Andrew W.	2-SUBSTITUTED-P-QUINONE
			Hinman;	DERIVATIVES FOR
			Kieron E.	TREATMENT OF OXIDATIVE
			Wesson;	STRESS DISEASES
			Orion D.	
			Jankowski;	
			William D.	
			Shrader;	
			Christopher r.	
			Cornell	

US	11083737	08/10/2021	Stephen P.	METHODS OF ADMINISTERING
			Wanaski; Virginia	DEFLAZACORT THERAPY
			D. Schmith;	
			Linda L.	
			Grasfeder; Scott	
			Joseph Brantley	

Pending Patent Applications

Country	Serial No.	Filing Date	Inventor(s)	<u>Title</u>
US	16/866822	04/06/2006	Samit	COMPOSITIONS FOR
			Hirawat;	AN ORALLY ACTIVE
			Langdon	1,2,4-OXADIAZOLE
			Miller	FOR THE TREATMENT
				OF DISEASE
US	17/602576	04/09/2020	Ronald Kong;	METHOD FOR
			Joseph	TREATING NONSENSE
			William	MUTATION
			Mcintosh	MEDIATED
				DUCHENNE
				MUSCULAR
				DYSTROPHY IN
				PEDIATRIC PATIENTS
US	17/216502	10/13/2009	Guy M. Miller	TREATMENT OF
				OXIDATIVE STRESS
				DISORDERS
				INCLUDING
				CONTRAST
				NEPHROPATHY,
				RADIATION DAMAGE
				AND DISRUPTIONS IN
				THE FUNCTION OF
				RED CELLS
US	14/038675	09/26/2013	Kieron E.	PROCESS FOR THE
			Wesson;	PRODUCTION OF
			Andrew W.	ALPHA-TOCOTRIENOL
			Hinman;	AND DERIVATIVES
			Orion D.	
			Jankowski	
US	17/699061	10/27/2009	Kieron E.	PROCESS FOR THE
			Wesson;	PRODUCTION OF
			Andrew W.	ALPHA-TOCOTRIENOL
			Hinman;	AND DERIVATIVES
			Orion D.	
			Jankowski	

US	17/511432	12/16/2016	Peter Giannousis; Paul Mollard; Noah M. Benjamin; Jeffrey D. Butler; Olivier Dapremont; James B. Falabella	METHODS FOR ENRICHING ALPHA- TOCOTRIENOL FROM MIXED TOCOL COMPOSITIONS
US	15/776343	11/15/2016	Seongwoo Hwang; Ellen Welch	HYDROGEN ISOTOPE- ENRICHED ANALOGUES OF 1,2,4- OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF
US	17/078092	10/11/2007	Samit Hirawat; Langdon Miller	METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4- OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY
US	17/490725	09/24/2007	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5-(2- FLUOROPHENYL)- [1,2,4]OXADIAZOL-3- YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE
US	17/183342	09/24/2007	Neil G. Almstead; Peter Seongwoo Hwang; Young-choon Moon	CRYSTALLINE FORMS OF 3-[5-(2- FLUOROPHENYL)- [1,2,4]OXADIAZOL-3- YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE
US	17/334601	06/01/2006	Guy M. Miller; Signey M. Hecht	REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL

				DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
US	17/400028	12/30/2010	Orion D. Jankowski; Kieron E. Wesson; Katsuyuki Murase; Guy M. Miller; Martin J. Thoolen	TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
US	17/394039	05/26/2017	Stephen P. Wanaski; Virginia D. Schmith; Linda L. Grasfeder; Scott Joseph Brantley	METHODS OF ADMINISTERING DEFLAZACORT THERAPY

Item B. <u>Patent Licenses</u> (excluding any licenses to the Grantor for open source or commercially available off- the-shelf software)

None.

RECORDED: 10/20/2023